Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kaleido Biosciences : Press Release issued by Kaleido Biosciences, Inc., dated August 11, 2021, furnished herewith (Form 8-K)

08/11/2021 | 08:27am EDT

--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter--

--Kaleido and the COPD Foundation to collaborate on the development of KB109 in patients with COPD; plan to initiate Phase 2 clinical study in first quarter 2022--

--Additional data from an observational clinical study of KB109 in patients with mild-to-moderate COVID-19 expected by end of third quarter--

LEXINGTON, MA-August 11, 2021-Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today reported financial results for the second quarter ended June 30, 2021.

'We have made considerable progress so far this year across our dynamic and diverse clinical pipeline of novel, targeted Microbiome Metabolic TherapyTM (MMT) candidates. We continue to advance KB295 in patients with mild-to-moderate ulcerative colitis and anticipate reporting topline data from the clinical study by the end of the third quarter,' said Dan Menichella, President and Chief Executive Officer of Kaleido. 'This quarter, we also expect to report data from the observational clinical study evaluating COVID-19 symptoms in 'Long Hauler' patients that participated in our prior COVID-19 clinical studies.'

Continued Mr. Menichella: 'Additionally, we are proud to have announced a strategic collaboration with the COPD Foundation, an organization uniquely qualified to aid us in our mission to improve the lives of patients suffering from COPD. Our KB109 program will be greatly enhanced with support from the COPD Foundation, and we look forward to a productive and mutually beneficial partnership that leverages the strong data from our COVID-19 studies to explore treatment of COPD, the most prevalent chronic respiratory illness, impacting over 250 million people worldwide. While we are prioritizing COPD based on our assessment of the unmet need and commercial opportunity, we will continue to evaluate development opportunities for KB109 in COVID-19 with partners and government agencies.'

Recent Program and Corporate Highlights

Topline data from the non-IND clinical study of KB295 in patients with mild-to-moderate ulcerative colitis (UC) are expected by the end of the third quarter.

Additional data from the observational clinical study of KB109 in patients with mild-to-moderate COVID-19 are expected by the end of the third quarter.

In August, Kaleido announced a collaboration with the COPD Foundation that is on track to initiate a Phase 2 clinical study of KB109 in patients with chronic obstructive pulmonary disease (COPD) in the first quarter of 2022.

1

Second Quarter Financial Results

Kaleido reported a net loss of $23.9 million, or $0.56 per common share, for the second quarter of 2021 compared to $18.9 million, or $0.59 per common share, for the same period in 2020. The second quarter net loss includes non-cash stock-based compensation expenses of $2.4 million, as compared to $2.8 million in the second quarter of 2020.

Research and development (R&D) expenses were $17.6 million and $12.8 million for the three months ended June 30, 2021 and 2020, respectively. The increase was primarily due to an increase in production of material for use in our clinical studies.

General and administrative (G&A) expenses were $5.8 million and $5.6 million for the three months ended June 30, 2021 and 2020, respectively. The increase was primarily due to increased facility operating costs that were attributed to general and administrative functions.

As of June 30, 2021, the Company reported cash and cash equivalents of $72.0 million and has cash runway into the second quarter of 2022.

About Microbiome Metabolic Therapies (MMT™)

Kaleido's Microbiome Metabolic Therapies, or MMTs, are designed to drive the function and distribution of the microbiome's existing microbes in order to decrease or increase the production of metabolites, or to advantage or disadvantage certain bacteria in the microbiome community. The Company's initial MMT candidates are targeted, synthetic glycans that are orally administered, have limited systemic exposure, and are selectively metabolized by enzymes in the microbiome. Kaleido utilizes its discovery and development platform to study MMTs in microbiome samples to rapidly advance MMT candidates rapidly into clinical studies in healthy subjects and patients. These human clinical studies are conducted under regulations supporting research with food, evaluating safety, tolerability and potential markers of effect. For MMT candidates that are further developed as therapeutics, the Company conducts clinical trials under an Investigational New Drug (IND) or regulatory equivalent outside the U.S., and in Phase 2 or later development.

About Kaleido Biosciences

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut's existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.

2

Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing of initiation, completion and reporting of results of clinical studies, and our anticipated regulatory filings, strategy, business plans and focus. The use of words such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in our stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering and those risks more fully discussed in the section entitled 'Risk Factors' in Kaleido's annual report on Form 10-K for the fiscal year ended December 31, 2020, which is available at www.sec.gov, as well as discussions of potential risks, uncertainties, and other important factors in Kaleido's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Kaleido's views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Kaleido undertakes no duty to update this information unless required by law.

3

Kaleido Biosciences, Inc. and Subsidiaries

Condensed Consolidated Statement of Operations (Unaudited)

(in thousands, except share and per share data)

Three Months Ended

June 30,

Six Months Ended

June 30,

2021

2020

2021

2020

Revenue:

Collaboration revenue

$

211

$

250

$

508

$

250

Operating expenses:

Research and development

17,633

12,833

34,818

25,970

General and administrative

5,785

5,559

11,245

11,476

Total operating expenses

23,418

18,392

46,063

37,446

Loss from Operations

(23,207

)

(18,142

)

(45,555

)

(37,196

)

Other (expense) income

(682

)

(780

)

(1,376

)

(1,277

)

Net loss

$

(23,889

)

$

(18,922

)

$

(46,931

)

$

(38,473

)

Net loss per share-basic and diluted

$

(0.56

)

$

(0.59

)

$

(1.14

)

$

(1.24

)

Weighted-average common shares outstanding-basic and diluted

42,538,563

31,880,672

41,123,435

31,106,977

Kaleido Biosciences, Inc. and Subsidiaries

Condensed Consolidated Balance Sheet Data (Unaudited)

(in thousands)

June 30, 2021

December 31, 2020

Assets:

Cash and cash equivalents

$

71,979

$

46,222

Other assets

12,311

13,122

Total assets

$

84,290

$

59,344

Liabilities and stockholders' equity

Liabilities

$

34,024

$

38,848

Stockholders' equity

50,266

20,496

Total liabilities and stockholders' equity

$

84,290

$

59,344

Contacts:
Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com

Investors and Media
Kotaro Yoshida
Argot Partners
212-600-1902

kaleido@argotpartners.com

4

Disclaimer

Kaleido Biosciences Inc. published this content on 11 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 August 2021 11:35:10 UTC.


© Publicnow 2021
All news about KALEIDO BIOSCIENCES, INC.
10/20NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
10/19KALEIDO BIOSCIENCES : Morgan Stanley Downgrades Kaleido Biosciences to Underweight from Eq..
MT
10/12KALEIDO BIOSCIENCES : to Participate in the Jefferies Virtual Next Generation IBD Therapeu..
AQ
10/05KALEIDO BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/05KALEIDO BIOSCIENCES : Says Bowel Disease Drug Trial Meets Primary Safety Endpoint
MT
10/05KALEIDO BIOSCIENCES : Announces New Clinical and Preclinical Data Supporting Advancement o..
AQ
10/05Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement ..
CI
09/29Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipel..
GL
09/29Kaleido Biosciences, Inc. to Host Virtual R&D Presentation to Discuss Clinical Data and..
CI
09/20KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) added to S&P Global BMI Index
CI
More news
Analyst Recommendations on KALEIDO BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 1,80 M - -
Net income 2021 -96,6 M - -
Net cash 2021 38,6 M - -
P/E ratio 2021 -2,03x
Yield 2021 -
Capitalization 188 M 188 M -
EV / Sales 2021 82,9x
EV / Sales 2022 103x
Nbr of Employees 82
Free-Float 91,0%
Chart KALEIDO BIOSCIENCES, INC.
Duration : Period :
Kaleido Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALEIDO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 4,42 $
Average target price 14,33 $
Spread / Average Target 224%
EPS Revisions
Managers and Directors
Daniel L. Menichella President, Chief Executive Officer & Director
William E. Duke Chief Financial Officer
Theo Melas-Kyriazi Chairman
Johan van Hylckama Vlieg Chief Scientific Officer
Kimberly Hocknell Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
KALEIDO BIOSCIENCES, INC.-51.43%188
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 092
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455